These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 17886294)

  • 1. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma.
    Ferrari S; Zanella L; Alberghini M; Palmerini E; Staals E; Bacchini P
    Pediatr Blood Cancer; 2008 Apr; 50(4):752-6. PubMed ID: 17886294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ezrin expression predicts survival in stage IIB osteosarcomas.
    Kim MS; Song WS; Cho WH; Lee SY; Jeon DG
    Clin Orthop Relat Res; 2007 Jun; 459():229-36. PubMed ID: 17353802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoexpression of Ezrin and CD44 in patients with osteosarcoma.
    Boldrini E; Peres SV; Morini S; de Camargo B
    J Pediatr Hematol Oncol; 2010 Aug; 32(6):e213-7. PubMed ID: 20562647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
    Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P
    Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
    J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
    Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
    J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ezrin in osteosarcoma: comparison between conventional high-grade and central low-grade osteosarcoma.
    Park HR; Jung WW; Bacchini P; Bertoni F; Kim YW; Park YK
    Pathol Res Pract; 2006; 202(7):509-15. PubMed ID: 16677779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preoperative and postoperative chemotherapy of osteogenic sarcoma of the limbs in children].
    Muñoz Villa A; Ocete G; Aymerich ML; Maldonado S; Otheo E; Calvo M; Amaya J
    Med Clin (Barc); 1996 Jun; 107(5):161-4. PubMed ID: 8758673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic factors for the local recurrence of osteosarcoma in extremities treated with combined therapy].
    Zhang Q; Niu XH; Cai YB; Hao L; Ding Y
    Zhonghua Wai Ke Za Zhi; 2007 Aug; 45(16):1114-7. PubMed ID: 18005614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ephrin A4 expression in osteosarcoma, impact on prognosis, and patient outcome.
    Abdou AG; Abd el-Wahed MM; Asaad NY; Samaka RM; Abdallaha R
    Indian J Cancer; 2010; 47(1):46-52. PubMed ID: 20071790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience.
    Mialou V; Philip T; Kalifa C; Perol D; Gentet JC; Marec-Berard P; Pacquement H; Chastagner P; Defaschelles AS; Hartmann O
    Cancer; 2005 Sep; 104(5):1100-9. PubMed ID: 16015627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of increased angiogenesis in osteosarcoma.
    Kreuter M; Bieker R; Bielack SS; Auras T; Buerger H; Gosheger G; Jurgens H; Berdel WE; Mesters RM
    Clin Cancer Res; 2004 Dec; 10(24):8531-7. PubMed ID: 15623635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
    Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G
    Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas.
    Weng WH; Ahlén J; Aström K; Lui WO; Larsson C
    Clin Cancer Res; 2005 Sep; 11(17):6198-204. PubMed ID: 16144921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic osteosarcoma.
    Daw NC; Billups CA; Rodriguez-Galindo C; McCarville MB; Rao BN; Cain AM; Jenkins JJ; Neel MD; Meyer WH
    Cancer; 2006 Jan; 106(2):403-12. PubMed ID: 16353204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer.
    Elzagheid A; Korkeila E; Bendardaf R; Buhmeida A; Heikkilä S; Vaheri A; Syrjänen K; Pyrhönen S; Carpén O
    Hum Pathol; 2008 Dec; 39(12):1737-43. PubMed ID: 18701134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol.
    Serra M; Pasello M; Manara MC; Scotlandi K; Ferrari S; Bertoni F; Mercuri M; Alvegard TA; Picci P; Bacci G; Smeland S
    Int J Oncol; 2006 Dec; 29(6):1459-68. PubMed ID: 17088985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic factors for 72 patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy].
    Liu J; Guo W; Yang RL; Tang XD; Yang Y
    Zhonghua Wai Ke Za Zhi; 2008 Aug; 46(15):1166-70. PubMed ID: 19094683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS).
    Kempf-Bielack B; Bielack SS; Jürgens H; Branscheid D; Berdel WE; Exner GU; Göbel U; Helmke K; Jundt G; Kabisch H; Kevric M; Klingebiel T; Kotz R; Maas R; Schwarz R; Semik M; Treuner J; Zoubek A; Winkler K
    J Clin Oncol; 2005 Jan; 23(3):559-68. PubMed ID: 15659502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases.
    Bacci G; Longhi A; Forni C; Fabbri N; Briccoli A; Barbieri E; Mercuri M; Balladelli A; Ferrari S; Picci P
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):505-11. PubMed ID: 17118571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.